ClinicalTrials.gg
CompletedNCT02987543Updated Oct 6, 2023Results posted

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

A Phase 3 interventional study of olaparib and enzalutamide in Metastatic Castration-resistant Prostate Cancer, sponsored by AstraZeneca. Completed at 204 sites in 20 countries. Open to male participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
387
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing olaparib in Prostatic Neoplasms — 2 open to participants now, 11 under way, 2 of them phase 3. olaparib · Prostatic Neoplasms.

Enrollment
4th of 25
387 · median 43
Started
2017
with 2 others
Phase 3
4 of 25
none open now
Registered
4th of 25
by date
Lead sponsor
5 of 25
AstraZeneca

Among the 25 studies testing olaparib in Prostatic Neoplasms, this one is the 4th largest by enrollment, is one of 3 that started in 2017, is one of 4 in phase 3, and was the 4th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 25 studies testing olaparib in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 130 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing olaparib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations.

Read the detailed description

This is a prospective, multicenter, randomized, open-label, phase 3 trial evaluating the efficacy and safety of olaparib versus enzalutamide or abiraterone in subjects with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior treatment with a new hormonal agent (NHA) and have a qualifying tumor mutation in one of 15 genes involved in the homologous recombination repair (HRR) pathway. Subjects will be divided into two cohorts based on HRR gene mutation status.

Approximately 340 subjects will be randomized 2:1 (olaparib : investigator choice of enzalutamide or abiraterone acetate) into the trial.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • metastatic castration-resistant prostate cancer (mCRPC)
  • homologous recombination repair (HRR)
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed diagnosis of prostate cancer.
  2. Documented evidence of castration resistant prostate cancer (mCRPC).
  3. Subjects must have progressed on prior new hormonal agent (e.g. abiraterone acetate and/or enzalutamide) for the treatment of metastatic prostate cancer and/or CRPC .
  4. Ongoing therapy with LHRH analog or bilateral orchiectomy.
  5. Radiographic progression at study entry while on androgen deprivation therapy (or after bilateral orchiectomy).
  6. Qualifying HRR mutation in tumor tissue.

Exclusion criteria

Exclusion criteria

  1. Any previous treatment with PARP inhibitor, including olaparib.
  2. Subjects who have any previous treatment with DNA-damaging cytotoxic chemotherapy, except if for non-prostate cancer indication and last dose > 5 years prior to randomization.
  3. Other (including MDS and MGUS) within the last 5 years except: adequately treated non-melanoma skin cancer or other solid tumors curatively treated with no evidence of disease for ≥5 years.
  4. Subjects with known .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
387 participants (actual)

Study arms

  • Experimental
    Olaparib

    Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose of 300 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions

    Drug: olaparib

  • Active comparator
    Enzalutamide OR abiraterone acetate

    Enzalutamide: Enzalutamide is available as capsules or tablets containing 40 mg of enzalutamide. Subjects will be administered study treatment orally at a dose of 160 mg once daily. Abiraterone acetate with prednisone: Abiraterone acetate is available as tablets containing 250 mg or 500 mg of abiraterone acetate. Subjects will be administered study treatment orally at a dose of 1,000 mg once daily in combination with prednisone 5 mg administered twice daily orally. Prednisolone is permitted for use instead of prednisone if necessary.

    Drug: enzalutamide · Drug: abiraterone acetate

Interventions

  • 300 mg (2x 150 mg tablets) twice daily

    Also known as: Lynparza

  • 160 mg (4 x 40 mg capsules) once daily

    Also known as: XTANDI

  • 1,000 mg (4 x 250 mg tablets) once daily

    Also known as: ZYTIGA

  • 1,000 mg (2 x 500 mg tablets) once daily

    Also known as: ZYTIGA

  • 160 mg (4 x 40 mg tablets) once daily

    Also known as: XTANDI

06

What researchers measure

Primary outcomes

  1. Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only

    The time from randomisation until the date of objective radiological disease progression (determined by RECIST 1.1 (soft tissue) and Prostate Cancer Working Group 3 (PCWG-3) (bone)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression. Progression is defined using (i) Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for soft tissue, as a \>=20% increase in the sum of diameters of target lesions and an absolute increase of \>=5mm taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters; (ii) Prostate Cancer Working Group 3 (PGWG-3) for bone as \>= 2 new bone lesions on the 1st week 8 scan compared to baseline. The confirmatory scan, \>=6 weeks later, must show \>=2 more new bone lesions (for a total of \>=4 new bone lesions since baseline).

    Time frame: Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).

Secondary outcomes

  1. Confirmed Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) - Cohort A Only

    ORR is the percentage of patients with at least one visit response of Complete response (CR) or Partial response (PR), in their soft tissue disease assessed by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), in the absence of progression on bone scan assessed by Prostate Cancer Working Group 3 (PCWG3)). Per RECIST v1.1, CR=Disappearance of all target lesions; PR = \>=30% decrease in the sum of diameters of target lesions; For each treatment group, ORR is the number of patients with a CR and PR.

    Time frame: Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).

  2. Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A+B

    The time from randomisation until the date of objective radiological disease progression (by RECIST 1.1 and Prostate Cancer Working Group 3 (PGWG-3)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression.

    Time frame: Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).

  3. Time to Pain Progression - Cohort A Only

    Time from randomisation to time point at which worsening in pain is observed (ie date of pain progression - date of randomisation + 1). Based on average Brief Pain Inventory - short form (BPI-SF) worst pain \[Item 3\] and Analgesic Quantification Algorithm \[AQA\] score.

    Time frame: Every 4 weeks from randomisation (for 7 consecutive days) throughout the study (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).

  4. Overall Survival (OS) - Cohort A Only

    Number of Participants with Overall Survival (OS) - Cohort A only.

    Time frame: Approximately 35 months after the first patient was randomised.

07

Results

Posted Oct 12, 2020

Participant flow

Subjects were divided into two cohorts based on HRR gene mutation status. Subjects with mutations in either BRCA1, BRCA2, or ATM are in Cohort A whereas subjects with mutations among 12 other genes involved in the HRR pathway (BARD1, BRIP1, CDK12, CHEK1,CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, or RAD54L) are in Cohort B.

Participant flow — Overall Study
MilestoneCohort A Olaparib 300mg bdCohort A Investigators Choice of NHACohort B Olaparib 300mg bdCohort B Investigators Choice of NHA
Started162839448
Completed0000
Not completed162839448
Withdrew: Ongoing study at data cut off49211912
Withdrew: Death88546728
Withdrew: Lost to follow-up3010
Withdrew: Screen failure0001
Withdrew: Withdrawal by subject21776
Withdrew: Study terminated by sponsor1000
Withdrew: Investigator decision0100
Withdrew: Disease progression0001

Outcome measures

SecondaryConfirmed Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) - Cohort A Only

ORR is the percentage of patients with at least one visit response of Complete response (CR) or Partial response (PR), in their soft tissue disease assessed by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), in the absence of progression on bone scan assessed by Prostate Cancer Working Group 3 (PCWG3)). Per RECIST v1.1, CR=Disappearance of all target lesions; PR = \>=30% decrease in the sum of diameters of target lesions; For each treatment group, ORR is the number of patients with a CR and PR.

Time frame:
Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).
Reported as:
Count of participants · Participants
Confirmed Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) - Cohort A Only
ParticipantsCohort A Olaparib 300mg bdCohort A Investigators Choice of NHA
Response281
No response5642
Statistical analysis
  • Cohort A Olaparib 300mg bd vs Cohort A Investigators Choice of NHA · Regression, Logistic · p = <0.0001 · Odds ratio (or): 20.86 · 95% CI 4.18 to 379.18
SecondaryRadiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A+B

The time from randomisation until the date of objective radiological disease progression (by RECIST 1.1 and Prostate Cancer Working Group 3 (PGWG-3)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression.

Time frame:
Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).
Reported as:
Median · Months
Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A+B
MonthsCohort A Olaparib 300mg bdCohort A Investigators Choice of NHA
Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A+B5.82 (5.52 to 7.36)3.52 (2.2 to 3.65)
Statistical analysis
  • Cohort A Olaparib 300mg bd vs Cohort A Investigators Choice of NHA · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 0.49 · 95% CI 0.38 to 0.63
SecondaryTime to Pain Progression - Cohort A Only

Time from randomisation to time point at which worsening in pain is observed (ie date of pain progression - date of randomisation + 1). Based on average Brief Pain Inventory - short form (BPI-SF) worst pain \[Item 3\] and Analgesic Quantification Algorithm \[AQA\] score.

Time frame:
Every 4 weeks from randomisation (for 7 consecutive days) throughout the study (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).
Reported as:
Median · Months
Time to Pain Progression - Cohort A Only
MonthsCohort A Olaparib 300mg bdCohort A Investigators Choice of NHA
Time to Pain Progression - Cohort A OnlyNA (NA to NA)9.92 (5.39 to NA)
Statistical analysis
  • Cohort A Olaparib 300mg bd vs Cohort A Investigators Choice of NHA · Regression, Cox · p = 0.0192 · Hazard ratio (hr): 0.44 · 95% CI 0.22 to 0.91
SecondaryOverall Survival (OS) - Cohort A Only

Number of Participants with Overall Survival (OS) - Cohort A only.

Time frame:
Approximately 35 months after the first patient was randomised.
Reported as:
Count of participants · Participants
Overall Survival (OS) - Cohort A Only
ParticipantsCohort A Olaparib 300mg bdCohort A Investigators Choice of NHA
Died9157
Alive at data cut-off4921
Terminated prior to death (withdrawn consent)225
Statistical analysis
  • Cohort A Olaparib 300mg bd vs Cohort A Investigators Choice of NHA · Regression, Cox · p = 0.0175 (2-sided p-value) · Hazard ratio (hr): 0.69 · 95% CI 0.50 to 0.97
PrimaryRadiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only

The time from randomisation until the date of objective radiological disease progression (determined by RECIST 1.1 (soft tissue) and Prostate Cancer Working Group 3 (PCWG-3) (bone)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression. Progression is defined using (i) Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for soft tissue, as a \>=20% increase in the sum of diameters of target lesions and an absolute increase of \>=5mm taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters; (ii) Prostate Cancer Working Group 3 (PGWG-3) for bone as \>= 2 new bone lesions on the 1st week 8 scan compared to baseline. The confirmatory scan, \>=6 weeks later, must show \>=2 more new bone lesions (for a total of \>=4 new bone lesions since baseline).

Time frame:
Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).
Reported as:
Median · Months
Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only
MonthsCohort A Olaparib 300mg bdCohort A Investigators Choice of NHA
Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only7.39 (6.24 to 9.33)3.55 (1.91 to 3.71)
Statistical analysis
  • Cohort A Olaparib 300mg bd vs Cohort A Investigators Choice of NHA · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 0.34 · 95% CI 0.25 to 0.47

Adverse events

Collected over From the time of signature of informed consent throughout the treatment period (median duration of treatment of 7.5 and 3.9 months for Olaparib and Investigators Choice of NHA respectively) up to and including the 30-day follow-up period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A+B Olaparib 300mg bd160/256 (62.5%)94/256 (36.7%)241/256 (94.1%)
Cohort A+B Investigators Choice of NHA88/131 (67.2%)39/130 (30%)112/130 (86.2%)
Most frequent serious events
Showing 10 of 119
Most frequent serious events
EventCohort A+B Olaparib 300mg bdCohort A+B Investigators Choice of NHA
AnaemiaBlood and lymphatic system disorders23/2560/130
PneumoniaInfections and infestations11/2564/130
Urinary tract infectionInfections and infestations5/2564/130
SepsisInfections and infestations3/2563/130
DehydrationMetabolism and nutrition disorders0/2563/130
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/2561/130
ThrombocytopeniaBlood and lymphatic system disorders4/2560/130
VomitingGastrointestinal disorders4/2561/130
AstheniaGeneral disorders4/2561/130
DyspnoeaRespiratory, thoracic and mediastinal disorders4/2561/130
Most frequent other events
Showing 10 of 29
Most frequent other events
EventCohort A+B Olaparib 300mg bdCohort A+B Investigators Choice of NHA
AnaemiaBlood and lymphatic system disorders110/25620/130
NauseaGastrointestinal disorders109/25626/130
Decreased appetiteMetabolism and nutrition disorders78/25624/130
FatigueGeneral disorders68/25628/130
DiarrhoeaGastrointestinal disorders54/2569/130
ConstipationGastrointestinal disorders49/25619/130
VomitingGastrointestinal disorders49/25617/130
AstheniaGeneral disorders37/25618/130
Back painMusculoskeletal and connective tissue disorders36/25617/130
Oedema peripheralGeneral disorders34/25610/130

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort A Olaparib 300mg bdCohort A Investigators Choice of NHACohort B Olaparib 300mg bdCohort B Investigators Choice of NHATotal
Mean68.0 ± 8.2368.1 ± 7.3669.2 ± 8.7970.3 ± 7.8368.6 ± 8.15
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A Olaparib 300mg bdCohort A Investigators Choice of NHACohort B Olaparib 300mg bdCohort B Investigators Choice of NHATotal
Female00000
Male162839448387
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A Olaparib 300mg bdCohort A Investigators Choice of NHACohort B Olaparib 300mg bdCohort B Investigators Choice of NHATotal
White109555430248
Black or African American21508
Asian43192617105
Other11103
Missing778123
08

Study locations

204 sites
  • Research Site
    Anchorage, Alaska 99503, United States
  • Research Site
    Tucson, Arizona 85704, United States
  • Research Site
    Tucson, Arizona 85741, United States
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    San Diego, California 92161, United States
  • Research Site
    Santa Barbara, California 93105, United States
  • Research Site
    Washington, District of Columbia 20007, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Atlanta, Georgia 30318, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Jeffersonville, Indiana 47130, United States
  • Research Site
    New Orleans, Louisiana 70112, United States
  • Research Site
    Baltimore, Maryland 21287, United States
  • Research Site
    Towson, Maryland 21204, United States
  • Research Site
    Omaha, Nebraska 68130, United States
  • Research Site
    Las Vegas, Nevada 89135, United States
  • Research Site
    Albany, New York 12208, United States
  • Research Site
    Bronx, New York 10468, United States
  • Research Site
    Brooklyn, New York 11201, United States
  • Research Site
    Syracuse, New York 13210, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Salisbury, North Carolina 28144, United States
  • Research Site
    Columbus, Ohio 43230, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Springfield, Oregon 97477, United States
  • Research Site
    Tualatin, Oregon 97062, United States
  • Research Site
    Charleston, South Carolina 29401, United States
  • Research Site
    Myrtle Beach, South Carolina 29572, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Salt Lake City, Utah 84112, United States
  • Research Site
    Salt Lake City, Utah 84148, United States
  • Research Site
    Spokane, Washington 99202, United States
  • Research Site
    Wheeling, West Virginia 26003, United States
  • Research Site
    Buenos Aires, 1426, Argentina
  • Research Site
    Buenos Aires, C1118AAT, Argentina
  • Research Site
    Buenos Aires, C1120AAT, Argentina
  • Research Site
    Caba, C1280AEB, Argentina
  • Research Site
    La Rioja, 5300, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Greenslopes, 4120, Australia
  • Research Site
    Herston, 4029, Australia
  • Research Site
    Macquarie University, 2109, Australia
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    Nedlands, 6009, Australia
  • Research Site
    Randwick, 2031, Australia
  • Research Site
    Waratah, 2298, Australia
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Linz, 4020, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Wien, 1020, Austria
  • Research Site
    Wien, 1090, Austria
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Belo Horizonte, 30110-022, Brazil
  • Research Site
    Curitiba, 80530-010, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Passo Fundo, 99010-080, Brazil
  • Research Site
    Porto Alegre, 90160-093, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Recife, 50040-000, Brazil
  • Research Site
    Ribeirao Preto, 14015-140, Brazil
  • Research Site
    Rio de Janeiro, 22793-080, Brazil
  • Research Site
    Santo Andre, 09060-650, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01321-001, Brazil
  • Research Site
    São Paulo, 03102-002, Brazil
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
  • Research Site
    Oakville, Ontario L6H 3P1, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Chicoutimi, Quebec G7H 5H6, Canada
  • Research Site
    Montreal, Quebec H2X 3E4, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Research Site
    Quebec, G1J 1Z4, Canada
  • Research Site
    Odense C, 5000, Denmark
  • Research Site
    BESANCON Cedex, 25030, France
  • Research Site
    Bordeaux Cedex, 33000, France
  • Research Site
    Caen, 14000, France
  • Research Site
    Lille, 59020, France
  • Research Site
    Lyon Cedex 08, 69008, France
  • Research Site
    Marseille cedex 09, 13273, France
  • Research Site
    Montpellier, 34298, France
  • Research Site
    Paris, 75014, France
  • Research Site
    Poitiers Cedex, 86021, France
  • Research Site
    Saint Herblain, 44805, France
  • Research Site
    Toulouse Cedex 09, 31100, France
  • Research Site
    Vandoeuvre les Nancy, 54519, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Bergisch Gladbach, 51465, Germany
  • Research Site
    Berlin, 13055, Germany
  • Research Site
    Bremen, 28277, Germany
  • Research Site
    Duisburg, 47179, Germany

Showing the first 100 of 204 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Roubaud G, Ozguroglu M, Penel N, Matsubara N, Mehra N, Kolinsky MP, Procopio G, Feyerabend S, Joung JY, Gravis G, Nishimura K, Gedye C, Padua C, Shore N, Thiery-Vuillemin A, Saad F, van Alphen R, Carducci MA, Desai C, Brickel N, Poehlein C, Del Rosario P, Fizazi K. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. Eur J Cancer. 2022 Jul;170:73-84. doi: 10.1016/j.ejca.2022.04.016. Epub 2022 May 19. PubMed 35598359 ↗
  • Matsubara N, Nishimura K, Kawakami S, Joung JY, Uemura H, Goto T, Kwon TG, Sugimoto M, Kato M, Wang SS, Pang ST, Chen CH, Fujita T, Nii M, Shen L, Dujka M, Hussain M, de Bono J. Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis. Jpn J Clin Oncol. 2022 May 5;52(5):441-448. doi: 10.1093/jjco/hyac015. PubMed 35229141 ↗
  • Thiery-Vuillemin A, de Bono J, Hussain M, Roubaud G, Procopio G, Shore N, Fizazi K, Dos Anjos G, Gravis G, Joung JY, Matsubara N, Castellano D, Degboe A, Gresty C, Kang J, Allen A, Poehlein C, Saad F. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Mar;23(3):393-405. doi: 10.1016/S1470-2045(22)00017-1. Epub 2022 Feb 11. Erratum In: Lancet Oncol. 2022 Apr;23(4):e161. doi: 10.1016/S1470-2045(22)00146-2. PubMed 35157830 ↗
  • Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, Sandhu S, Mateo J, Olmos D, Mehra N, Kolinsky MP, Roubaud G, Ozguroglu M, Matsubara N, Gedye C, Choi YD, Padua C, Kohlmann A, Huisden R, Elvin JA, Kang J, Adelman CA, Allen A, Poehlein C, de Bono J. Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). Clin Cancer Res. 2022 Apr 14;28(8):1518-1530. doi: 10.1158/1078-0432.CCR-21-3940. PubMed 35091440 ↗
  • Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Ozguroglu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20. PubMed 32955174 ↗
  • de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28. PubMed 32343890 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jun 2019, 27 months.

Results were first posted in Oct 2020, 1 year 4 months after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 27 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2016
First posted
Dec 9, 2016
StartActual
Feb 6, 2017
Primary completionActual
Jun 4, 2019
CompletionActual
Feb 15, 2023
Results first posted
Oct 12, 2020
Last update
Oct 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02987543
Lead sponsor
AstraZeneca
Collaborators
Merck Sharp & Dohme LLC, Foundation Medicine, Myriad Genetics, Inc.
Responsible party
Sponsor
First posted
Dec 9, 2016
Start date
Feb 6, 2017
Primary completion
Jun 4, 2019
Completion
Feb 15, 2023
Results posted
Oct 12, 2020
Last update
Oct 6, 2023

Study contacts

Johann de Bono, M.D., Ph.D.
principal investigator · The Institute of Cancer Research, United Kingdom
Maha Hussain, M.D., FACP, FASCO
principal investigator · Northwestern University, United States of America

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion